PDCD1 and neoplasm: The mechanistic basis for ICI therapy is that the PD-L1 expression in cells within tumor environments is also considered to be essential because anti-PD-1/PD-L1 antibodies target and inhibit the interaction between PD-1 and PD-L1, restoring immune activity in the tumor environment.